Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
$13.57
-2.0%
$14.25
$7.05
$17.15
$356.45M0.3756,695 shs23,359 shs
Elutia Inc. stock logo
ELUT
Elutia
$2.45
-0.4%
$1.89
$1.61
$5.12
$100.74M0.8841,749 shs54,862 shs
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
$4.82
-3.4%
$4.62
$2.86
$16.62
$329.44M1.9821,858 shs199,649 shs
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
$6.97
-8.0%
$7.78
$6.59
$21.79
$264.70M-0.11134,892 shs58,648 shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
+9.67%+8.63%-14.41%+15.91%+50.11%
Elutia Inc. stock logo
ELUT
Elutia
+8.37%+13.89%+30.16%+9.82%-47.21%
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
+7.78%+9.91%+13.93%+46.33%-56.68%
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
+5.73%+4.13%-6.66%-3.57%-51.35%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
2.1499 of 5 stars
3.62.00.00.03.00.80.0
Elutia Inc. stock logo
ELUT
Elutia
3.1449 of 5 stars
3.55.00.00.00.03.30.6
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
2.2537 of 5 stars
3.51.00.00.00.02.50.6
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
3.3558 of 5 stars
3.62.00.00.01.82.51.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
3.20
Buy$23.8375.70% Upside
Elutia Inc. stock logo
ELUT
Elutia
3.00
Buy$8.00226.53% Upside
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
3.00
Buy$24.50408.51% Upside
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
3.25
Buy$25.67268.51% Upside

Current Analyst Ratings Breakdown

Latest ELUT, TRDA, OLMA, and BNTC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/7/2025
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
5/20/2025
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
5/19/2025
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
5/15/2025
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$20.00 ➝ $20.00
5/14/2025
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$20.00 ➝ $18.00
5/14/2025
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$25.00 ➝ $22.00
5/9/2025
Elutia Inc. stock logo
ELUT
Elutia
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$10.00 ➝ $8.00
4/28/2025
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
4/10/2025
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$18.00 ➝ $20.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
$80K4,451.02N/AN/A$4.68 per share2.90
Elutia Inc. stock logo
ELUT
Elutia
$24.38M4.13N/AN/A($1.31) per share-1.87
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
N/AN/AN/AN/A$7.14 per shareN/A
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
$210.78M1.25$1.54 per share4.51$11.46 per share0.61
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
-$21.75M-$1.51N/AN/AN/AN/A-38.26%-35.71%9/25/2025 (Estimated)
Elutia Inc. stock logo
ELUT
Elutia
-$53.95M-$1.93N/AN/AN/A-168.23%N/A-96.70%7/28/2025 (Estimated)
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
-$129.47M-$2.01N/AN/AN/AN/A-42.31%-38.32%8/5/2025 (Estimated)
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
$65.63M$0.818.61N/AN/A14.39%5.84%4.61%8/12/2025 (Estimated)

Latest ELUT, TRDA, OLMA, and BNTC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
-$0.44N/AN/AN/AN/AN/A
5/14/2025Q3 2025
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
-$0.36-$0.24+$0.12-$0.24N/AN/A
5/13/2025Q1 2025
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
-$0.49-$0.36+$0.13-$0.36N/AN/A
5/8/2025Q1 2025
Elutia Inc. stock logo
ELUT
Elutia
-$0.20-$0.21-$0.01-$0.21$6.65 million$6.03 million
5/8/2025Q1 2025
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
-$0.78-$0.42+$0.36-$0.42$10.98 million$8.75 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
N/AN/AN/AN/AN/A
Elutia Inc. stock logo
ELUT
Elutia
N/AN/AN/AN/AN/A
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
N/AN/AN/AN/AN/A
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
0.01
14.80
14.80
Elutia Inc. stock logo
ELUT
Elutia
N/A
0.81
0.70
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
N/A
15.22
15.22
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
N/A
21.88
21.88

Institutional Ownership

CompanyInstitutional Ownership
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
52.19%
Elutia Inc. stock logo
ELUT
Elutia
74.03%
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
91.78%
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
86.39%

Insider Ownership

CompanyInsider Ownership
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
1.30%
Elutia Inc. stock logo
ELUT
Elutia
27.60%
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
16.36%
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
8.11%
CompanyEmployeesShares OutstandingFree FloatOptionable
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
2026.25 million25.91 millionNo Data
Elutia Inc. stock logo
ELUT
Elutia
18041.12 million29.77 millionNot Optionable
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
7068.42 million57.23 millionOptionable
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
11037.95 million34.88 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Benitec Biopharma stock logo

Benitec Biopharma NASDAQ:BNTC

$13.56 -0.28 (-1.99%)
As of 02:05 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

Elutia stock logo

Elutia NASDAQ:ELUT

$2.45 -0.01 (-0.41%)
As of 02:03 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.

Olema Pharmaceuticals stock logo

Olema Pharmaceuticals NASDAQ:OLMA

$4.82 -0.17 (-3.45%)
As of 02:06 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Entrada Therapeutics stock logo

Entrada Therapeutics NASDAQ:TRDA

$6.96 -0.61 (-7.99%)
As of 02:05 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.